Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felipe Martinez

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2025
FDG PET of the brain to screen for neurodegenerative disease in older liver transplant candidatesNatalie Jones, Trent M Schwartz, Steven Bishay, et al.
JAMA Cardiology|November 3, 2022
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
Cardiovascular Diabetology|July 31, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialMohammad Abdel Jawad, Remo H M Furtado, Russell Esterline, et al.
Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
Circulation|October 21, 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFLi Shen, Pooja Dewan, João Pedro Ferreira, et al.
Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2025
FDG PET of the brain to screen for neurodegenerative disease in older liver transplant candidatesNatalie Jones, Trent M Schwartz, Steven Bishay, et al.
JAMA Cardiology|November 3, 2022
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
Cardiovascular Diabetology|July 31, 2025
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trialMohammad Abdel Jawad, Remo H M Furtado, Russell Esterline, et al.
Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Journal of the American College of Cardiology|August 30, 2022
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection FractionJawad H Butt, Toru Kondo, Pardeep S Jhund, et al.
Circulation|October 21, 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFLi Shen, Pooja Dewan, João Pedro Ferreira, et al.
Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Pageof 14